Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-17T13:18:53.836Z Has data issue: false hasContentIssue false

P0285 - Clozapine in outpatient treatment of patients with non-responsive schizophrenia and depressive symptoms

Published online by Cambridge University Press:  16 April 2020

E. Miceva-Velickoska
Affiliation:
University Clinic of Psychiatry, Skopje, Macedonia
N. Manuseva
Affiliation:
University Clinic of Psychiatry, Skopje, Macedonia
S. Bajraktarov
Affiliation:
Psychiatric Hospital *Skopje*, Skopje, Macedonia
V. Calovska-Samardziska
Affiliation:
University Clinic of Psychiatry, Skopje, Macedonia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aims:

Clozapine is the first atypical antipsychotic with main indication in the treatment of refractory schizophrenia. The aim of this study was to explore clinical response to clozapine in patients with schizophrenia non-responsive to other antipsychotics and who also have symptoms of depression.

Methods:

The descriptive retrospective study included 25 patients on clozapine followed up for 6 months period with clinical scales: BPRS and PANSS.

Results:

The achievments obtained and described in remission of symptomatology and improvement in quality of life. A significant reduction in rehospitalization is reported and also in the use of services of psychiatric emergencies.

Conclusions:

This form of treatment is beneficial and most appropriate for patients with refractory schizophrenia and depressive symptoms.

Type
Poster Session I: Neuroleptics and Antipsychotics
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.